机译:核受体基因多态性和华法林剂量要求在魁北克华法林队列中
Univ Montreal Beaulieu Saucier Pharmacogen Ctr Montreal PQ Canada;
Univ Montreal Beaulieu Saucier Pharmacogen Ctr Montreal PQ Canada;
Univ Montreal Beaulieu Saucier Pharmacogen Ctr Montreal PQ Canada;
Univ Montreal Beaulieu Saucier Pharmacogen Ctr Montreal PQ Canada;
Univ Montreal Beaulieu Saucier Pharmacogen Ctr Montreal PQ Canada;
Univ Montreal Beaulieu Saucier Pharmacogen Ctr Montreal PQ Canada;
Univ Montreal Beaulieu Saucier Pharmacogen Ctr Montreal PQ Canada;
Univ Montreal Beaulieu Saucier Pharmacogen Ctr Montreal PQ Canada;
Univ Montreal Beaulieu Saucier Pharmacogen Ctr Montreal PQ Canada;
Univ Montreal Beaulieu Saucier Pharmacogen Ctr Montreal PQ Canada;
Univ Montreal Beaulieu Saucier Pharmacogen Ctr Montreal PQ Canada;
Univ Montreal Fac Pharm Montreal PQ Canada;
Univ Montreal Beaulieu Saucier Pharmacogen Ctr Montreal PQ Canada;
机译:核受体基因多态性和华法林剂量要求在魁北克华法林队列中
机译:ABCB1 2677G> T单核苷酸多态性影响华法林维持治疗的华法林剂量要求
机译:VKORC1 VKORC1和CYP2C9 CYP2C9基因多态性与伊朗Birjand City的一组华法林用户中的Warfarin维持剂量的关系
机译:CYP4F2 V433M多态性和华法林剂量
机译:新型基于遗传的华法林剂量诺模图的开发和验证。
机译:魁北克华法林队列中的核受体基因多态性和华法林剂量要求
机译:VKORC1,CYP2C9,mEPHX1,因子VII,R353Q和NQO1基因多态性与华法林维持剂量要求,华法林的药物毒性和伊朗丘疹之间的关联